$XBI $124.51 +0.50%
Pipeline Updates
$INO -0.3% INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201 source
$CYDY +2.0% Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada source
$SIGA +1.7% European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat source
$CRSP +1.8% CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes source
$IMRA -8.8% IMARA ANNOUNCES INTERIM ANALYSIS DATA FROM FORTE PHASE 2B CLINICAL TRIAL OF TOVINONTRINE (IMR-687) IN TRANSFUSION-DEPENDENT SUBJECTS WITH BETA-THALASSEMIA source
$CDAK -3.5% Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts source
$CYDY +2.0% CytoDyn Submits the First of Three Main Sections of HIV BLA to FDA Under Previously Authorized Rolling Review source
Business Updates
$EYPT -1.8% EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock source
$AVIR -11.4% Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche source
$OPTN -33.5% Optinose Announces Pricing of Public Offering of Common Stock source
$APLS +12.0% Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock source
Posted by JM
Comments